My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 308

    1.

    The effect of rosiglitazone on overweight subjects with type 1 diabetes.

    Strowig SM, Raskin P.

    Diabetes Care. 2005 Jul;28(7):1562-7.PMID: 15983301 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

    Roberts VL, Stewart J, Issa M, Lake B, Melis R.

    Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

    3.

    Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

    Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

    4.

    Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

    Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

    Diabetes Care. 2006 Mar;29(3):554-9.PMID: 16505505 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.

    Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J; Rosiglitazone Clinical Trials Study Group.

    Diabetes Care. 2001 Jul;24(7):1226-32.PMID: 11423507 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

    Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

    Clin Ther. 2005 Sep;27(9):1383-91.PMID: 16291411 [PubMed - indexed for MEDLINE]Related articles

    7.

    Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

    Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

    Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

    8.

    Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

    Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

    J Clin Pharm Ther. 2006 Aug;31(4):375-83.PMID: 16882108 [PubMed - indexed for MEDLINE]Related articles

    9.

    Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.

    Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander P.

    Diabetes Care. 2002 Jun;25(6):1033-41. Erratum in: Diabetes Care. 2003 Mar;26(3):971.. PMID: 12032111 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.

    Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, Knight D, Grossman L, Oakley D, Tan M; H6E-MC-GLAT study group.

    Clin Ther. 2005 May;27(5):554-67.PMID: 15978304 [PubMed - indexed for MEDLINE]Related articles

    11.

    Effect of pioglitazone therapy in lean type 1 diabetes mellitus.

    Bhat R, Bhansali A, Bhadada S, Sialy R.

    Diabetes Res Clin Pract. 2007 Dec;78(3):349-54. Epub 2007 May 31.PMID: 17543413 [PubMed - indexed for MEDLINE]Related articles

    12.

    The addition of rosiglitazone to insulin in adolescents with type 1 diabetes and poor glycaemic control: a randomized-controlled trial.

    Stone ML, Walker JL, Chisholm D, Craig ME, Donaghue KC, Crock P, Anderson D, Verge CF.

    Pediatr Diabetes. 2008 Jul 28;9(4 Pt 1):326-34. Epub 2008 May 7.PMID: 18466213 [PubMed - indexed for MEDLINE]Related articles

    13.

    Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetes.

    Hollander P, Yu D, Chou HS.

    Arch Intern Med. 2007 Jun 25;167(12):1284-90.PMID: 17592102 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes.

    Gómez-Perez FJ, Fanghänel-Salmón G, Antonio Barbosa J, Montes-Villarreal J, Berry RA, Warsi G, Gould EM.

    Diabetes Metab Res Rev. 2002 Mar-Apr;18(2):127-34.PMID: 11994904 [PubMed - indexed for MEDLINE]Related articles

    15.

    A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.

    Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR.

    Clin Ther. 2007 Sep;29(9):1900-14.PMID: 18035190 [PubMed - indexed for MEDLINE]Related articles

    16.

    Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes.

    Natali A, Baldeweg S, Toschi E, Capaldo B, Barbaro D, Gastaldelli A, Yudkin JS, Ferrannini E.

    Diabetes Care. 2004 Jun;27(6):1349-57.PMID: 15161787 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.

    Bailey CJ, Bagdonas A, Rubes J, McMorn SO, Donaldson J, Biswas N, Stewart MW.

    Clin Ther. 2005 Oct;27(10):1548-61.PMID: 16330291 [PubMed - indexed for MEDLINE]Related articles

    18.

    Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.

    Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A; Rosiglitazone Clinical Trials Study Group.

    Diabetes Care. 2001 Feb;24(2):308-15. Erratum in: Diabetes Care 2001 May;24(5):973. PMID: 11213884 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

    Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A.

    Diabetes Care. 2007 Feb;30(2):217-23. Erratum in: Diabetes Care. 2007 May;30(5):1330. PMID: 17259484 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.

    Patel J, Anderson RJ, Rappaport EB.

    Diabetes Obes Metab. 1999 May;1(3):165-72.PMID: 11220295 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity